A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

NCT04501276 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Solid Tumors

Interventions

DRUG: ADG116
DRUG: ADG106
DRUG: anti PD1 drug

Sponsor

Adagene Inc